Multicenter study of subcutaneous alemtuzumab administered at reduced dose in patients with fludarabine-relapsed/refractory chronic lymphocytic leukemia: Final analysis

Leukemia and Lymphoma

Volumn 52, Issue 10, 2011, Pages 1936-1941

  Bezares, Raimundo Fernando ^b   Stemelin, German ^a   Diaz, Alicia ^b   Argentieri, Daniel ^c   Zubiaur, Emilio Lanari ^d   Garay, Guy ^e   Bartomioli, Miguel ^f   Ryser, Ricardo ^g   Milone, Gustavo ^h  

^a HOSPITAL BRITÁNICO DE BUENOS AIRES   (Argentina)

^b HOSPITAL DURAND   (Argentina)

^c Department of Hematology   (Argentina)

^d Department of Hematology   (Argentina)

^e CEMIC   (Argentina)

^f Hospital Privado del Sur   (Argentina)

^g Sanatorio Del Salvador   (Argentina)

^h Fundaleu ^*  (Argentina)

Author keywords

Antibody based immunotherapy; CLL; immunotherapeutic approaches

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; ASPARTATE AMINOTRANSFERASE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLUDARABINE; ITRACONAZOLE; RITUXIMAB;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACTERIAL INFECTION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HUMAN; INJECTION SITE REACTION; LEUKEMIA RELAPSE; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MUCORMYCOSIS; MULTICENTER STUDY; NEUTROPENIA; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PILOT STUDY; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT RESPONSE; VIRUS REACTIVATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PILOT PROJECTS; SALVAGE THERAPY; SURVIVAL ANALYSIS; VIDARABINE;

EID: 80053209157     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.584991     Document Type: Article

References (13)

1. Dumont FJ. Alemtuzumab (Millenium/ILEX). Curr Opin Investig Drugs 2001;2:139-160.
2. Keating MJ, Flinn I, Vinay J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002;99:3554-3561. (Pubitemid 34534522)
3. Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616-5623.
4. Lundin J, Kimby E, Björkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100: 768-773. (Pubitemid 34832599)
5. Rieger K, Von Grunhagen U, Fietz T, et al. Efficacy and tolerability of alemtuzumab (Campath 1H) in the salvage treatment of B-cell chronic lymphocytic leukemiachange of regimen needed? Leuk Lymphoma 2004;45:345-349. (Pubitemid 38181439)
6. Thieblemont C, Bouafia F, Hornez E, et al. Maintenance therapy with a monthly injection of alemtuzumab prolongs response duration in patients with refractory B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/ SLL). Leuk Lymphoma 2004;45:711-714. (Pubitemid 38256030)
7. Rebello P, Cwynarski K., Varughese M, et al. Pharmacokinetics of Campath-1H in BMT patients. Cytotherapy 2001;3:261-267. (Pubitemid 34784622)
8. Elter T, Molnar I, Kuhlmann J, et al. Pharmacokinetics of alemtuzumab and the relevance in clinical practice. Leuk Lymphoma 2008;49:2256-2262.
9. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-4997. (Pubitemid 26189840)
10. Montillo M, Tedeschi A, Migueletz S, et al. Alemtuzumab as consolidation after a response to fludarabine is effective in purging residual disease in patients with chronic lymphocytic leukemia. J Clin Oncol 2006;24:2337-2342. (Pubitemid 46630666)
11. Cortelezzi A, Pasquini MC, Gardellini U, et al. Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia(CLL): results of a prospective, single-arm multicentre study. Leukemia 2010;24:890-891.
12. Montagna M, Montillo M, Avanzini MA, et al. Pharmacokinetics (PK) of alemtuzumab after subcutaneous (sc) administration for consolidation in patients with CLL. Haematologica 2009; 94(Suppl. 3):S71
13. Mould DR, Baumann A, Kuhlmann J, et al. Population pharmacokinetics- pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response. Br J Clin Pharmacol 2007;64:278-291. (Pubitemid 47283867)